For research use only. Not for therapeutic Use.
Prasinezumab（Cat No.:I042194）is a monoclonal antibody designed to target alpha-synuclein, a protein implicated in neurodegenerative diseases like Parkinson’s disease. Abnormal accumulation of alpha-synuclein in the brain is a hallmark of these conditions, contributing to the progression of neurodegeneration. By binding to and potentially preventing the aggregation of alpha-synuclein, prasinezumab aims to slow disease progression and protect against neuronal damage. It is being studied in clinical trials for Parkinson’s disease to assess its safety, efficacy, and potential to improve cognitive and motor function in patients with early-stage disease.
| Catalog Number | I042194 |
| CAS Number | 1960462-19-4 |
| Purity | ≥95% |
